IRVINE, Calif., & LIEGE, Belgium--(BUSINESS WIRE)--MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, confirmed today that it continues to make progress on partnering of its technology and companion diagnostics tests with pharmaceutical companies.
